Latest news from the FASST trial
The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.
Read latest newsletter on the research: FASST Newsletter, May2016
news & events
A tool for rheumatologists and other healthcare professionals for RMD patients.
Skin care is very important when you have systemic sclerosis.
Come with us on a roadtrip along with Scleroderma Framed in order to spread awareness of Scleroderma.